1188913-39-4

Basic information

• Product Name: (E)-1-benzyl-4-((5,6-diMethoxy-1-oxo-1H-inden-2(3H)-ylidene)Methyl)pyridiniuM chloride
• Synonyms: (E)-1-benzyl-4-((5,6-diMethoxy-1-oxo-1H-inden-2(3H)-ylidene)Methyl)pyridiniuM chloride;(E)-1-benzyl-4-((5,6-dimethoxy-1-oxo-1H-inden-2(3H)-ylidene)methyl)pyridin-1-ium chloride
• CAS NO: 1188913-39-4
• Molecular Formula: C24H22ClNO3
• Molecular Weight: 407.88938
• Mol File: 1188913-39-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-1-benzyl-4-((5,6-diMethoxy-1-oxo-1H-inden-2(3H)-ylidene)Methyl)pyridiniuM chloride(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-1-benzyl-4-((5,6-diMethoxy-1-oxo-1H-inden-2(3H)-ylidene)Methyl)pyridiniuM chloride(1188913-39-4)
• EPA Substance Registry System: (E)-1-benzyl-4-((5,6-diMethoxy-1-oxo-1H-inden-2(3H)-ylidene)Methyl)pyridiniuM chloride(1188913-39-4)

Safety Data

• Hazardous Substances Data: 1188913-39-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(E)-1-benzyl-4-((5,6-dimethoxy-1-oxo-1H-inden-2(3H)-ylidene)methyl)pyridinium chloride is used as a reactant in the preparation of Donepezil Hydrochloride (D531750), a nootropic. (E)-1-benzyl-4-((5,6-dimethoxy-1-oxo-1H-inden-2(3H)-ylidene)methyl)pyridinium chloride plays a crucial role in the synthesis of Donepezil, which is a medication used to treat Alzheimer's disease and improve cognitive function by enhancing cholinergic neurotransmission. Its involvement in the production of Donepezil highlights its significance in the development of therapeutic agents for neurological disorders.

Upstream product

• 872-85-5 pyridine-4-carbaldehyde 
• 2107-69-9 5,6-dimethoxy-1-indanone 
• 4803-74-1 5,6-dimethoxy-2-[(pyridin-4-yl)methylene]-1-indanone 
• 100-44-7 benzyl chloride 

Relevant articles and documents

Synthesis, characterization and investigation of AChE and BuChE inhibitory activity of 1-alkyl-4-[(5,6-dimethoxy-1-indanone-2-yl)methylene]pyridinium halide derivatives

Abstract: The design, synthesis and characterization of a series of 1-alkyl-4-[(5,6-dimethoxy-1-indanone-2-yl)methylene]pyridinium halide derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors for the treatment of Alzheimer’s disease were reported. The strategy for this synthesis was based on aldol condensation reaction between 4-pyridinecarboxaldehyde with 5,6-dimethoxy-1-indanone in the presence of NaOH in EtOH-H2O solution as the first step and N-alkylation reaction of the produced 5,6-dimethoxy-2-[(pyridin-4-yl)methylene]-1-indanone with various alkyl halides (R–X) in the second step. This reaction was carried out under reflux temperature in polar aprotic solvents such as acetone or acetonitrile. 1H and 13C NMR and FTIR spectroscopy along with CHN analysis were used to confirm the structure of our synthesized compounds. Biological activities including acetylcholinesterase and butyrylcholinesterase (BuChE) inhibitions for synthesized compounds were tested using the Ellman method. The results were compared with donepezil and galantamine, and among the synthesized compounds, the highest inhibitory activity with BuChE IC50 = 0.55?μM was observed. Graphic abstract: [Figure not available: see fulltext.]